Market News AIOpen the app

The Japan Patent Office gave XORTX Therapeutics a patent for its XRx-101 program to treat kidney injuries.

TrialRead the original at globenewswire.com
Good for XRTX

XORTX's Japan patent decision could protect a treatment approach for kidney injury and related organ damage. That supports its drug program, though registration remains pending and no treatment results are reported.

XRTX · XORTX Therapeutics Inc.

AI read · Good for XRTX

The AI's read

This gives XORTX added protection around a treatment approach as it advances its programs. Registration is still pending, and the company reports no treatment results.

Get alerts for XRTX

Follow XORTX Therapeutics Inc. (XRTX) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for XRTX
Free on the App Store and Google Play, or on the web.